Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. More Details
Excellent balance sheet with high growth potential.
Share Price & News
How has Altimmune's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 18% a week.
Volatility Over Time: ALT's weekly volatility has decreased from 24% to 18% over the past year, but is still higher than 75% of US stocks.
7 Day Return
1 Year Return
Return vs Industry: ALT exceeded the US Biotechs industry which returned 36% over the past year.
Return vs Market: ALT exceeded the US Market which returned 21% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Altimmune's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall StHere's Why We're Not At All Concerned With Altimmune's (NASDAQ:ALT) Cash Burn Situation
4 weeks ago | Simply Wall StAltimmune (NASDAQ:ALT) Shareholders Have Enjoyed A Whopping 620% Share Price Gain
2 months ago | Simply Wall StEarnings Update: Altimmune, Inc. (NASDAQ:ALT) Just Reported And Analysts Are Trimming Their Forecasts
Is Altimmune undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ALT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ALT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ALT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ALT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALT is good value based on its PB Ratio (2.2x) compared to the US Biotechs industry average (4.3x).
How is Altimmune forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: ALT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ALT's is expected to become profitable in the next 3 years.
Revenue vs Market: ALT's revenue (44.7% per year) is forecast to grow faster than the US market (10.2% per year).
High Growth Revenue: ALT's revenue (44.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALT's Return on Equity is forecast to be high in 3 years time
How has Altimmune performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALT is currently unprofitable.
Growing Profit Margin: ALT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALT is unprofitable, and losses have increased over the past 5 years at a rate of 16.4% per year.
Accelerating Growth: Unable to compare ALT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: ALT has a negative Return on Equity (-21.29%), as it is currently unprofitable.
How is Altimmune's financial position?
Financial Position Analysis
Short Term Liabilities: ALT's short term assets ($218.1M) exceed its short term liabilities ($6.3M).
Long Term Liabilities: ALT's short term assets ($218.1M) exceed its long term liabilities ($27.0M).
Debt to Equity History and Analysis
Debt Level: ALT is debt free.
Reducing Debt: ALT has no debt compared to 5 years ago when its debt to equity ratio was 3.2%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ALT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Altimmune current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Vipin Garg (62 yo)
Dr. Vipin K. Garg, Ph.D. has been President, Chief Executive Officer and Director of Altimmune, Inc. since November 30, 2018. Dr. Garg served as Advisor of Neos Therapeutics, Inc. since June 27, 2018 until...
CEO Compensation Analysis
Compensation vs Market: Vipin's total compensation ($USD566.63K) is below average for companies of similar size in the US market ($USD1.65M).
Compensation vs Earnings: Vipin's compensation has been consistent with company performance over the past year.
|CFO & Principal Accounting Officer||2.67yrs||US$594.72k||0.043% |
|Chief Medical Officer||1.5yrs||US$542.62k||0.011% |
|Chief Technology Officer||3.67yrs||no data||no data|
|Chief Scientific Officer||8.08yrs||US$290.39k||0.025% |
|Chief Business Officer||2.5yrs||no data||no data|
Experienced Management: ALT's management team is considered experienced (2.6 years average tenure).
|Independent Chairman||3yrs||US$121.89k||0.071% |
|Independent Director||16.42yrs||US$85.43k||0.030% |
|Independent Director||3.67yrs||US$92.43k||0.049% |
|Independent Director||3.67yrs||US$95.93k||0.088% |
|Member of Scientific Advisory Board||no data||no data||no data|
|Member of Scientific Advisory Board||no data||no data||no data|
|Independent Director||8.5yrs||US$85.93k||0.024% |
|Independent Director||2.42yrs||US$92.93k||0.023% |
|Independent Director||0.67yr||no data||0% |
Experienced Board: ALT's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ALT insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 146.2%.
Altimmune, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Altimmune, Inc.
- Ticker: ALT
- Exchange: NasdaqGM
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$477.997m
- Shares outstanding: 36.97m
- Website: https://altimmune.com
Number of Employees
- Altimmune, Inc.
- 910 Clopper Road
- Suite 201S
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ALT||NasdaqGM (Nasdaq Global Market)||Yes||Common Shares||US||USD||May 2017|
|3G0||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||May 2017|
|0A4C||LSE (London Stock Exchange)||Yes||Common Shares||GB||USD||May 2017|
Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/16 00:26|
|End of Day Share Price||2021/01/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.